Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

One-third of IDH1-mutated AML cases have complete response to ivosidenib

Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.

Key clinical point: Daily oral ivosidenib was associated with a complete response rate of nearly 32% and a low rate of serious adverse events in patients with IDH1-mutated relapsed/refractory acute myeloid leukemia (AML).

Major finding: Patients with complete responses had an 8.2-month duration of response, and a median overall survival of 18.8 months.

Study details: A phase 1 study including 179 patients who received 500 mg of ivosidenib daily.

Disclosures: Daniel A. Pollyea, MD, who presented the study, reported disclosures related to Abbvie, Agios, argenx, Celgene, Celyad, Curis, Pfizer, and Servier.

Source: Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.

Read the article.

Citation:

Pollyea DA, et al. J Clin Oncol 36, 2018 (suppl) annual meeting of the American Society of Clinical Oncology; abstr 7000.

This Week's Must Reads

Gene sequencing bone marrow in myelodysplastic syndrome, Duncavage EJ et al. N Engl J Med 2018;379:1028-41.

Levofloxacin prophylaxis in ALL, AML , Alexander S, et al. JAMA. 2018;320(10):995-1004

Genetic markers signal poor prognosis in MCL, Obr A et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 23. doi: 10.1016/j.clml.2018.07.282

Disparities in ALL treatment toxicity, Taylor OA et al. Clin Cancer Res. 2018 Sep 11. doi: 10.1158/1078-0432.CCR-18-0939

Leukemia risk after maternal contraception use, Hargreave M et al. Lancet Oncol. 2018 Sep 6. doi: 10.1016/S1470-2045(18)30479-0

Must Reads in AML

Levofloxacin prophylaxis in ALL, AML , Alexander S, et al. JAMA. 2018;320(10):995-1004

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Vadastuximab talirine improves AML remission rates, Fathi AT et al. Blood. 2018 Jul 25. doi: 10.1182/blood-2018-03-841171.

Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release

Second filgrastim biosimilar approved by FDA, U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi), Pfizer press release